Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Keymed-Lepu JV Out-Licenses Claudin 18.2 ADC to AstraZeneca in $1.2 Billion Agreement

publication date: Feb 23, 2023

Chengdu Keymed Bio and Lepu Biopharma out-licensed global rights for their partnered Claudin 18.2 antibody drug conjugate to AstraZeneca in a deal that includes $63 million upfront and up to $1.1 billion in milestones. KYM Biosciences, a JV formed by Keymed and Lepu, is currently conducting a China Phase I trial of CMG901 in patients with Claudin 18.2-positive solid tumors including gastric cancers. Preliminary results suggest that CMG901 has a favorable safety and tolerability profile, with an encouraging response rate of 75% among eight patients. Keymed believes the candidate has first-in-class potential. More details....

Stock Symbols: (HK: 02162) (HK: 02157) (NSDQ: AZN)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital